Oral Edaravone Administration Timing for Consistent Absorption
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Edaravone, used as a therapeutic agent for ALS, is currently only available in injectable form and its oral administration is affected by meal types, leading to variations in pharmacokinetics.
Innovation Solution
Administering edaravone orally or intragastrically with specific time intervals after meals, such as 8 hours after a high-fat meal, 4 hours after a standard meal, or 2 hours after a light meal, to minimize meal effects on its pharmacokinetics.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If edaravone is administered orally without specific timing restrictions, then ease of operation is improved, but manufacturing precision deteriorates due to variability in drug absorption and concentration
Solution Approach 1:
The patent applies preliminary action by establishing specific timing conditions before administration (fasting for 10 hours or more, or specific intervals after meals) to ensure optimal absorption conditions are met before the drug is taken, thereby controlling absorption variability while maintaining oral administration
2Ease of operation
If edaravone is administered immediately after meals, then ease of operation is improved, but reliability deteriorates due to inconsistent pharmacokinetic parameters
Solution Approach 1:
The patent establishes preliminary conditions regarding meal timing and composition before administration, requiring specific intervals (2-8 hours depending on meal type) to elapse before taking the drug, ensuring reliable pharmacokinetic parameters while allowing flexible administration timing
3Manufacturing precision
If edaravone is administered with strict fasting requirements, then manufacturing precision is improved through consistent absorption, but ease of operation deteriorates due to dietary restrictions
Solution Approach 1:
The patent provides multiple preliminary timing options (10-hour fast, 8-hour post-high-fat meal, 4-hour post-standard meal, 2-hour post-light meal) that all achieve consistent absorption, giving patients flexibility in choosing when to take the drug while maintaining manufacturing precision
Solution Approach 2:
The patent changes the parameter of fasting duration based on meal type and composition, allowing shorter fasting periods after light meals compared to high-fat meals, thereby maintaining absorption consistency while improving administrative flexibility
Data Source
AI summary
A method of treating an oxidative stress disease includes orally or intragastrically administering, to a subject in need thereof, a pharmaceutical composition including edaravone with a time interval from a consumption of a meal by the subject in need thereof to an administration of the pharmaceutical composition to the subject in need thereof. The time interval is 8 hours or longer after the consumption of a high-fat meal, the time interval is 4 hours or longer after the consumption of a standard meal, or the time interval is 2 hours or longer after the consumption of a light meal.


